| Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival, frequency of relapse, and outcomes compared to single-seropositive patients SP McAdoo, A Tanna, Z Hrušková, L Holm, M Weiner, N Arulkumaran, ... Kidney international 92 (3), 693-702, 2017 | 224 | 2017 |
| Sodium‐Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta‐Analysis C Arnott, Q Li, A Kang, BL Neuen, S Bompoint, CSP Lam, A Rodgers, ... Journal of the American Heart Association 9 (3), e014908, 2020 | 212 | 2020 |
| The effect of folic acid based homocysteine lowering on cardiovascular events in people with kidney disease: systematic review and meta-analysis MJ Jardine, A Kang, S Zoungas, SD Navaneethan, T Ninomiya, ... Bmj 344, e3533, 2012 | 150 | 2012 |
| Interventions for lowering plasma homocysteine levels in dialysis patients SU Nigwekar, A Kang, S Zoungas, A Cass, MP Gallagher, S Kulshrestha, ... Cochrane Database of Systematic Reviews, 2016 | 56 | 2016 |
| High Incidence of Arterial and Venous Thrombosis in Antineutrophil Cytoplasmic Antibody–associated Vasculitis A Kang, M Antonelou, NL Wong, A Tanna, N Arulkumaran, FWK Tam, ... The Journal of rheumatology 46 (3), 285-293, 2019 | 43 | 2019 |
| SGLT2 inhibitors may offer benefit beyond diabetes A Kang, MJ Jardine Nature Reviews Nephrology 17 (2), 83-84, 2021 | 38 | 2021 |
| Incidence and Associations of Chronic Kidney Disease in Community Participants With Diabetes: A 5-Year Prospective Analysis of the EXTEND45 Study L Sukkar, A Kang, C Hockham, T Young, M Jun, C Foote, R Pecoits-Filho, ... Diabetes Care, 2020 | 21 | 2020 |
| Prevalence, incidence and risk factors of diabetes in Australian adults aged≥ 45 years: A cohort study using linked routinely-collected data H Zhang, K Rogers, L Sukkar, M Jun, A Kang, T Young, A Campain, ... Journal of clinical & translational endocrinology 22, 100240, 2020 | 19 | 2020 |
| Effect of Hemodiafiltration on the Progression of Neuropathy with Kidney Failure A Kang, R Arnold, M Gallagher, P Snelling, J Green, M Fernando, ... Clinical Journal of the American Society of Nephrology, 2021 | 17 | 2021 |
| Sodiumglucose cotransporter 2 inhibition for the prevention of cardiovascular events in patients with type 2 diabetes mellitus: a systematic review and Meta-analysis. J Am … C Arnott, Q Li, A Kang, BL Neuen, S Bompoint, CSP Lam, A Rodgers, ... | 16 | |
| Interventions for lowering plasma homocysteine levels in kidney transplant recipients A Kang, SU Nigwekar, V Perkovic, S Kulshrestha, S Zoungas, ... Cochrane Database of Systematic Reviews, 2015 | 15 | 2015 |
| EXamining ouTcomEs in chroNic Disease in the 45 and Up Study (the EXTEND45 Study): Protocol for an Australian Linked Cohort Study C Foote, C Hockham, L Sukkar, A Campain, A Kang, T Young, A Cass, ... JMIR Research Protocols 9 (4), e15646, 2020 | 12 | 2020 |
| Impact of treatment on damage and hospitalization in elderly patients with microscopic polyangiitis and granulomatosis with polyangiitis M Weiner, SM Goh, AJ Mohammad, Z Hrušková, A Tanna, P Sharp, ... The Journal of rheumatology, jrheum. 190019, 2019 | 10 | 2019 |
| Relationship between measured and prescribed dialysate sodium in haemodialysis: a systematic review and meta-analysis JKC Ng, B Smyth, MR Marshall, A Kang, J Pinter, A Bassi, R Krishnasamy, ... Nephrology Dialysis Transplantation 36 (4), 695-703, 2021 | 8 | 2021 |
| Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA1c, disease duration and … TK Young, JW Li, A Kang, HJL Heerspink, C Hockham, C Arnott, ... Diabetologia, 1-13, 2021 | 7 | 2021 |
| Randomised controlled trial of the impact of haemodiafiltration on uraemic neuropathy: FINESSE study protocol B Smyth, AV Krishnan, M Gallagher, M Kiernan, P Snelling, C Hawley, ... BMJ open 9 (1), e023736, 2019 | 7 | 2019 |
| Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial TW Yi, B Smyth, GL Di Tanna, C Arnott, K Cardoza, A Kang, C Pollock, ... American Journal of Kidney Diseases, 2023 | 6 | 2023 |
| The impact of canagliflozin on the risk of neuropathy events: a post-hoc exploratory analysis of the CREDENCE trial J Liao, A Kang, C Xia, T Young, GL Di Tanna, C Arnott, C Pollock, ... Diabetes & Metabolism, 101331, 2022 | 4 | 2022 |
| Risk Factors for Incident Kidney Disease in Older Adults: an Australian Prospective Population‐Based Study A Kang, L Sukkar, C Hockham, M Jun, T Young, A Scaria, C Foote, ... Internal Medicine Journal, 2020 | 4 | 2020 |
| Risk Factors for Fracture in Patients with Coexisting Chronic Kidney Disease and Type 2 Diabetes: An Observational Analysis from the CREDENCE Trial TK Young, ND Toussaint, GL Di Tanna, C Arnott, C Hockham, A Kang, ... Journal of Diabetes Research 2022, 2022 | 3 | 2022 |
